Pick1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
PICK1 (Protein Interacting with C Kinase 1) is a versatile scaffolding protein that contains a PDZ domain and a BAR (Bin/amphiphysin/Rvs) domain, enabling it to interact with multiple protein partners and organize signaling complexes at synaptic membranes. Originally identified as an interacting protein for protein kinase C (PKC), PICK1 plays critical roles in synaptic plasticity, receptor trafficking, and neuronal signaling. PICK1 is highly enriched in the brain, particularly at excitatory synapses where it interacts with AMPA receptor subunits (GluA2/3), dopamine transporters, and various other membrane proteins. Through its BAR domain, PICK1 can sense and induce membrane curvature, facilitating the formation of synaptic vesicles and receptor endocytosis. Dysregulation of PICK1 function has been implicated in synaptic dysfunction in Alzheimer's disease, Parkinson's disease, and psychiatric disorders including schizophrenia and addiction.
| PICK1 Protein | |
|---|---|
| Protein Name | PICK1 Protein |
| Gene | PICK1 |
| UniProt ID | Q9YEP4 |
| PDB IDs | 18K5, 2GZO |
| Molecular Weight | 46.2 kDa |
| Subcellular Location | Cytoplasm, postsynaptic density |
| Protein Family | PDZ domain proteins |
PICK1 Protein is a PDZ domain proteins. The protein contains a BAR domain for membrane binding and a PDZ domain for protein-protein interactions.
PICK1 (Protein Interacting with C Kinase 1) is a PDZ domain-containing scaffold protein that interacts with protein kinase C (PKC) and various membrane proteins including AMPA receptors, NMDA receptors, and dopamine transporters. PICK1 contains an N-terminal BAR domain that binds curved membranes and a C-terminal PDZ domain that interacts with target proteins. It is involved in synaptic plasticity, receptor trafficking, and the formation of excitatory synapses.
PICK1 is implicated in AD (altered AMPA receptor trafficking, synaptic dysfunction), PD (dopamine transporter regulation), and schizophrenia. PICK1 polymorphisms may be associated with neuropsychiatric disorders.
No specific PICK1-targeted drugs are available. Modulation of PICK1 interactions could potentially be used to treat synaptic disorders.
The study of Pick1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.